Alzamend Neuro is partnering with Mass General Hospital for a Phase 2 trial of AL001, a next-generation lithium drug for ...

Wallowing in self-pity is tempting in the wake of an Alzheimer's diagnosis, but it's crucial to keep moving forward, says columnist.

Fosgonimeton, an investigational medication from Athira Pharma, failed to significantly improve cognitive and daily functioning in adults with mild to moderate Alzheimer’s disease who took part in a ...

While Alzheimer’s disease (AD) has no cure, five prescription medicines have been approved by the U.S. Food and Drug Administration (FDA) to treat disease symptoms that impact thinking and memory.

Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

Experimental treatments being developed to address the underlying cause of Alzheimer’s disease mostly target beta-amyloid plaques and tau protein tangles, which are thought to be the main players in ...

The approved drugs for Alzheimer’s disease do not address the underlying cause of the disease, but instead treat only the symptoms. However, there is a vast array of experimental treatments that are ...

Treatment with CT1812, previously called Elayta, slowed the decline of cognitive function among adults with mild to moderate Alzheimer’s disease in a proof-of-concept clinical trial dubbed SHINE. That ...

Amylyx Pharmaceuticals‘ investigational oral therapy AMX0035 reduces the levels of several biomarkers associated with Alzheimer’s disease, according to an analysis of data from the PEGASUS trial. “The ...